Date: 2016-12-20
Type of information: Licensing agreement
Compound: NG-348
Company: BMS (USA - NY) PsiOxus Therapeutics (UK)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: immunotherapy product/oncolytic virus. NG-348 is a Tumor-Specific Immuno-Gene Therapy (T-SIGn) virus designed to drive T-cell immune responses locally within the tumor microenvironment. It is a transgene-modified variant of enadenotucirev encoding two immunomodulatory MiTe proteins in its genome. The two MiTe proteins encoded within NG-348 are a membrane anchored full-length human CD80 and a membrane anchored antibody fragment specific for the T-cell receptor CD3 protein When expressed together on the surface of NG-348 infected tumor cells, these two membrane proteins provide both the T-cell receptor and costimulatory activation signals required to polyclonally activate tumor-infiltrating T-cells in an antigen independent manner.
Disease: solid tumors
Details: * On December 20, 2016, PsiOxus Therapeutics has announced an agreement granting BMS exclusive worldwide rights to NG-348, a pre-clinical stage, "armed" oncolytic virus which may serve as a novel mechanism to address solid tumours. This announcement is the second collaboration between PsiOxus and BMS and follows an agreement announced in June 2016 under the terms of which the two companies entered into an exclusive clinical collaboration to study enadenotucirev, PsiOxus' systemically administered "unarmed" oncolytic adenovirus therapeutic.
Financial terms: Under the terms of the agreement, BMS will grant PsiOxus a $50 million upfront payment and will be solely responsible for global clinical development and commercialisation activities related to NG-348. PsiOxus is also eligible to receive up to $886 million in development, regulatory and sales-based milestones, and in addition, royalties on net sales. BMS will also be responsible for providing PsiOxus funding to support activities related to the preclinical development of NG-348.
Latest news:
